Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.
The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). Sixty-six participants (18%) with Polypoidal Choroidal Vasculopathy (PCV) out of a total stu...
>>> Read more: Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration
The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). Sixty-six participants (18%) with Polypoidal Choroidal Vasculopathy (PCV) out of a total stu...
>>> Read more: Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration
